Document ID: chunk:federal_register_of_legislation:C2025C00090:section:99adhb:p2
Version: federal_register_of_legislation:C2025C00090
Segment Type: section
Provision Reference: s 99ADHB (pt 2/2)
Character Range: 404046–405979

the Minister must take into account what the approved ex‑manufacturer price, and (if applicable) the claimed price, of the existing brand of the combination item would otherwise be under this section in relation to the particular reduction day if a determination were not made; and
 (b) the Minister may take into account:
 (i) any advice given to the Minister under subsection 101(4AC) in relation to the combination item; and
 (ii) any other matter the Minister thinks is relevant.
 (6B) If the Minister makes a determination under subsection (6), the approved ex‑manufacturer price of the existing brand of the combination item is not to be further reduced under this section on any reduction day that occurs after the reduction day specified in the determination made under subsection (6).

Section does not limit Minister's powers
 (6C) This section does not limit the Minister's powers, on or after the reduction day, to make:
 (a) further price agreements; or
 (b) determinations under section 85B;
for the existing brand of the combination item.

Modified meaning of the same manner of administration
 (7) For the purposes of this section, the existing brand of the combination item has the same manner of administration as a pharmaceutical item that is not a combination item (the non‑combination item) if the manner of administration set out in a determination under subsection 85(5) for the combination item, to the extent that the manner of administration relates to the common drug, is the same as the manner of administration set out in a determination under subsection 85(5) for the non‑combination item.

Section does not limit Minister's powers
 (13) This section does not limit the Minister's powers, after the reduction day, to make further price agreements or determinations under section 85B in relation to the existing brand of the combination item.

Division 3BA—Floor price of a brand of a pharmaceutical item